NASDAQ:AEZSAEterna Zentaris Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AEterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.44 0.00 (0.00 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$0.42Now: $0.44▼$0.4550-Day Range$0.38MA: $0.93▼$1.2052-Week Range$0.37Now: $0.44▼$2.83Volume3.79 million shsAverage Volume1.12 million shsMarket Capitalization$10.25 millionP/E RatioN/ADividend YieldN/ABeta1.98 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. It also has a collaboration agreement with Sinopharm A-Think Pharmaceuticals Co., Ltd. for the development, manufacture, and commercialization of Zoptrex, which has completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer in the People's Republic of China. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for AEterna Zentaris. Previous Next 2.9 Community Rank Outperform VotesAEterna Zentaris has received 413 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAEterna Zentaris has received 307 “underperform” votes. (Add your “underperform” vote.)Community SentimentAEterna Zentaris has received 57.36% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote “Outperform” if you believe AEZS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AEZS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAEterna Zentaris does not currently pay a dividend.Dividend GrowthAEterna Zentaris does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AEterna Zentaris insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 5.21% of the stock of AEterna Zentaris is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of AEterna Zentaris is -21.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AEterna Zentaris is -21.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.58 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AEZS Previous Symbol CUSIPN/A CIK1113423 Webwww.zentaris.com Phone49-6942-6020Debt Debt-to-Equity Ratio0.09 Current Ratio3.46 Quick Ratio3.35Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$530,000.00 Price / Sales19.34 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-3.63Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-6,040,000.00 Net Margins-22.21% Return on EquityN/A Return on Assets-1.67%Miscellaneous EmployeesN/A Outstanding Shares23,510,000Market Cap$10.25 million Next Earnings Date8/11/2020 (Estimated) OptionableOptionable NASDAQ:AEZS Rates by TradingView Receive AEZS News and Ratings via Email Sign-up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter. AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions How has AEterna Zentaris' stock been impacted by COVID-19 (Coronavirus)? AEterna Zentaris' stock was trading at $0.6795 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AEZS stock has decreased by 35.8% and is now trading at $0.4360. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of AEterna Zentaris? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AEterna Zentaris in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AEterna Zentaris. When is AEterna Zentaris' next earnings date? AEterna Zentaris is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for AEterna Zentaris. How were AEterna Zentaris' earnings last quarter? AEterna Zentaris Inc. (NASDAQ:AEZS) posted its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, missing the consensus estimate of $1.68 by $1.64. The biopharmaceutical company had revenue of $1.09 million for the quarter. View AEterna Zentaris' earnings history. What are Wall Street analysts saying about AEterna Zentaris stock? Here are some recent quotes from research analysts about AEterna Zentaris stock: 1. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (11/5/2019) 2. HC Wainwright analysts commented, "We maintain our Buy rating of AEZS and our 12-month price target of $5.50 per share. We derive our price target using a risk- adjusted net present value analysis of potential US and EU royalties, discounted at 18%, to reach a total rNPV of $66M for the royalty streams." (8/15/2019) Has AEterna Zentaris been receiving favorable news coverage? Media headlines about AEZS stock have trended positive this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AEterna Zentaris earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about AEterna Zentaris. Are investors shorting AEterna Zentaris? AEterna Zentaris saw a drop in short interest in June. As of June 30th, there was short interest totaling 56,200 shares, a drop of 43.7% from the June 15th total of 99,900 shares. Based on an average trading volume of 382,200 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.2% of the company's shares are short sold. View AEterna Zentaris' Current Options Chain. Who are some of AEterna Zentaris' key competitors? Some companies that are related to AEterna Zentaris include Aileron Therapeutics (ALRN), Q BioMed (QBIO), Forward Pharma A/S (FWP), IMMUTEP LTD/S (IMMP), Akorn (AKRXQ), RegeneRx Biopharmaceuticals (RGRX), Bellicum Pharmaceuticals (BLCM), Pulmatrix (PULM), Diffusion Pharmaceuticals (DFFN), Annovis Bio (ANVS), Novan (NOVN), Adamis Pharmaceuticals (ADMP), Acerus Pharmaceuticals (ASPCF), Entasis Therapeutics (ETTX) and Acer Therapeutics (ACER). View all competitors. What other stocks do shareholders of AEterna Zentaris own? Based on aggregate information from My MarketBeat watchlists, some companies that other AEterna Zentaris investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), Zosano Pharma (ZSAN), CBL & Associates Properties (CBL), Chesapeake Energy (CHK), NGL Energy Partners (NGL), Pennsylvania R.E.I.T. (PEI), Trevena (TRVN), Ekso Bionics (EKSO) and Miragen Therapeutics (MGEN). Who are AEterna Zentaris' key executives? AEterna Zentaris' management team includes the following people: Mr. Michael V. Ward, Pres & CEO (Age 62)Ms. Leslie Auld, Sr. VP & CFOMr. Brian Garrison, Sr. VP of Global Corp. Operations & Corp. Devel.Dr. Nicola Ammer, Chief Medical Officer & VP of Clinical Devel.Mr. Olaf Althaus, GM & MD What is AEterna Zentaris' stock symbol? AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS." How do I buy shares of AEterna Zentaris? Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is AEterna Zentaris' stock price today? One share of AEZS stock can currently be purchased for approximately $0.44. How big of a company is AEterna Zentaris? AEterna Zentaris has a market capitalization of $10.25 million and generates $530,000.00 in revenue each year. What is AEterna Zentaris' official website? The official website for AEterna Zentaris is www.zentaris.com. How can I contact AEterna Zentaris? AEterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at 49-6942-6020 or via email at [email protected] This page was last updated on 7/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
